Renal Clear Cell Carcinoma malady

Disease Ontology: A renal cell carcinoma that is the most common type of renal cell carcinoma. the cancerous cells appear very pale or clear when examined under microscope. this cancer can be effectively treated with surgery if the tumor is confined to the kidney.⁶

MalaCards: Renal Clear Cell Carcinoma, also known as conventional (clear cell) renal cell carcinoma, is related to clear cell adenocarcinoma and chromophobe renal cell carcinoma. An important gene associated with Renal Clear Cell Carcinoma is CDH16 (cadherin 16, KSP-cadherin), and among its related pathways are Transcription Receptor-mediated HIF regulation and Transcription_Receptor-mediated HIF regulation. The compounds glucose and egcg have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and thyroid, and related mouse phenotypes are respiratory system and craniofacial.

Aliases & Descriptions:

renal clear cell carcinoma 6 8 32 conventional (clear cell) renal cell carcinoma 6 43 clear cell carcinoma of kidney (disorder) 6

conventional renal cell carcinoma 6 adenocarcinoma, clear cell 43

Diseases related to renal clear cell carcinoma by text searches and GeneDecks gene sharing:

(show top 50)    (show all 557)

id	Related Disease	Score	Top Affiliating Genes
1	clear cell adenocarcinoma	33.8	VEGFA, BIRC5, MTOR, CDH1, MET, ANXA4
2	chromophobe renal cell carcinoma	31.2	VIM, VHL, CLDN7, MUC1, S100A1, CDH16
3	renal cell carcinoma	29.8	RBX1, SETD2, VIM, VHL, VEGFA, RASSF1
4	clear cell renal cell carcinoma	27.7	SETD2, VIM, VHL, VEGFA, RASSF1, BIRC5
5	thrombosis	27.6	SETD2, VHL, VEGFA, MUC1, CD44, MMP2
6	retinoblastoma	23.6	VIM, VHL, VEGFA, VDR, BMI1, RASSF1
7	ischemia	23.5	GCK, SETD2, VIM, VHL, VEGFA, KDR
8	hypoxia	22.1	RBX1, SETD2, VHL, VEGFA, BIRC5, KDR
9	carcinoma	21.5	KLF10, GCK, RBX1, SETD2, VIM, VHL
10	thyroiditis	21.4	KLF10, GCK, RBX1, SETD2, VIM, VHL
11	adenocarcinoma	21.0	KLF10, SETD2, VIM, VHL, VEGFA, VDR
12	oxyphilic adenoma	14.0	CLDN7, S100A1, CDH16, CA9, PVALB
13	nephrogenic adenoma	13.9	MUC1, CDH16, AMACR, KRT7
14	horseshoe kidney	13.9	MME, CALB2, CA9, KRT7
15	endolymphatic sac tumor	13.9	SETD2, VHL, CA9, HIF1A, EPOR
16	adenofibroma	13.9	MME, INHA, CALB2, PTEN
17	mixed epithelial stromal tumour	13.9	MME, INHA, CALB2
18	metanephric adenoma	13.9	VIM, MUC1, AMACR, KRT7
19	papillary adenoma	13.9	VIM, AMACR, KRT7
20	sex cord-gonadal stromal tumor	13.9	VIM, INHA, CALB2
21	monophasic synovial sarcoma	13.9	RASSF1, MUC1, CALB2
22	cervical endometrioid adenocarcinoma	13.9	CALB2, PTEN, KRT7
23	cystic nephroma	13.9	VIM, MUC1, MME, KRT7
24	pleomorphic liposarcoma	13.9	VIM, INHA, CALB2
25	chondroid chordoma	13.8	VIM, MUC1, S100A1
26	malignant peritoneal mesothelioma	13.8	VIM, BIRC5, MUC1, CALB2
27	sertoli-leydig cell tumor	13.8	VIM, MUC1, INHA, CALB2, KRT7
28	rectum sarcomatoid carcinoma	13.8	VIM, MUC1, AMACR
29	malignant mixed mullerian tumor	13.8	VIM, MUC1, S100A1, KRT7
30	cutaneous leiomyosarcoma	13.8	VIM, MUC1, FH
31	ovarian sex cord tumors	13.8	VIM, MUC1, MME, CALB2, KRT7
32	tubular adenocarcinoma	13.8	MUC1, CDH1, MME, KRT7
33	leiomyomatosis	13.8	VIM, VHL, INHA, FH
34	central nervous system hemangioblastoma	13.8	VHL, MUC1, ANGPT4
35	adult glioblastoma multiforme	13.8	CA9, HIF1A, SLC2A1
36	glomus tumor	13.8	VIM, VHL, MUC1, S100A1
37	peutz-jeghers syndrome	13.8	VHL, MUC3A, MTOR, INHA, PTEN, HIF1A
38	hemangioendothelioma	13.8	VHL, VEGFA, KDR, CALB2, CAV1
39	leydig cell tumor	13.8	VIM, MUC1, INHA, FH, CALB2, KRT7
40	perineurioma	13.8	VIM, CLDN7, MUC1, SLC2A1
41	adenoid cystic carcinoma	13.8	VIM, RASSF1, MUC1, S100A1, CDH1, KRT7
42	primary polycythemia	13.8	VHL, EGLN1, EPOR
43	choroid plexus papilloma	13.8	VIM, RASSF1, MUC1, SLC2A1
44	spindle cell sarcoma	13.8	VIM, MUC1, KRT7
45	sarcomatoid renal cell carcinoma	13.8	VIM, VEGFA, MUC1, S100A1, CDH1, CA9
46	atypical teratoid rhabdoid tumor	13.8	VIM, RASSF1, MUC1, IGF1R
47	perivascular epithelioid cell tumor	13.8	VIM, MUC1, MTOR, S100A1
48	ossifying fibromyxoid tumor	13.8	VIM, S100A1, MME
49	neurilemmoma	13.8	VIM, MUC1, S100A1, INHA, CALB2
50	thoracic cancer	13.8	KDR, MSLN, CASP8, SLC2A1

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to renal clear cell carcinoma:

²²

MGI Mouse Phenotypes related to renal clear cell carcinoma:

²⁵ (show all 26)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	10.1	POLR2A, THRB, GSN
2	craniofacial phenotype	MP:0005382	9.9	THRB, THRA, EGLN2, IGF1R, BMI1
3	endocrine/exocrine gland phenotype	MP:0005379	9.6	EPB41L3, NKX2-1, THRA, DIO1, CAV1, CASP8
4	liver/biliary system phenotype	MP:0005370	9.5	POLR2A, THRA, HIF1A, ABCB1, AMACR, MET
5	embryogenesis phenotype	MP:0005380	9.2	TEK, EGLN1, EGLN2, G6PD, PSMC4, EPOR
6	normal phenotype	MP:0002873	9.0	G6PC, HIF1A, TGFBR2, PVALB, POLR2A, EPB41L3
7	limbs/digits/tail phenotype	MP:0005371	8.9	THRA, EGLN2, IGF1R, MET, CD44, BMI1
8	hematopoietic system phenotype	MP:0005397	8.6	BCL2, CLDN7, BMI1, VHL, INHA, FHIT
9	immune system phenotype	MP:0005387	8.5	EPOR, POLR2A, DKK3, VIM, VDR, BMI1
10	no phenotypic analysis	MP:0003012	8.5	THRB, POLR2A, SLC2A1, NKX2-1, EPOR, RHEBL1
11	renal/urinary system phenotype	MP:0005367	8.4	CAV1, PTEN, DIO1, CYP24A1, EGLN1, G6PC
12	adipose tissue phenotype	MP:0005375	8.2	PTEN, THRA, TGFA, TGFB1, TGFBR2, CAV1
13	skeleton phenotype	MP:0005390	7.8	IGF1R, CAV1, PTEN, CYP24A1, HIF1A, THRA
14	integument phenotype	MP:0010771	7.7	ANGPT2, IGF1R, CASP8, CAV1, EGLN1, EGLN2
15	reproductive system phenotype	MP:0005389	7.6	CYP24A1, EGLN2, THRA, THRB, TGFB1, PSMC4
16	behavior/neurological phenotype	MP:0005386	7.5	PTEN, ABCB1, G6PC, THRA, THRB, TGFBR2
17	digestive/alimentary phenotype	MP:0005381	6.7	HIF1A, DIO1, PTEN, CAV1, CA9, THRA
18	vision/eye phenotype	MP:0005391	6.3	ANGPT2, PTEN, HIF1A, THRA, THRB, TGFA
19	nervous system phenotype	MP:0003631	5.9	THRA, HIF1A, G6PD, G6PC, THRB, TG
20	muscle phenotype	MP:0005369	5.8	CASP8, CAV1, TEK, PTEN, EGLN1, EGLN2
21	tumorigenesis	MP:0002006	5.7	THRB, THRA, HIF1A, PTEN, CAV1, IGF1R
22	mortality/aging	MP:0010768	5.5	VHL, SETD2, RBX1, GCK, VEGFA, EPOR
23	growth/size phenotype	MP:0005378	5.3	NKX2-1, SLC2A1, POLR2A, TGFBR2, TGFBI, TGFA
24	cellular phenotype	MP:0005384	4.7	THRA, HIF1A, G6PD, ABCB1, EGLN2, EGLN1
25	cardiovascular system phenotype	MP:0005385	4.1	EGLN2, CDKN1B, CDK2, S100A1, BCL2, KDR
26	homeostasis/metabolism phenotype	MP:0005376	2.2	G6PD, G6PC, ABCC1, ABCB1, EGLN2, EGLN1

Articles related to renal clear cell carcinoma:

(show all 37)

id	Title	Authors	Year	Affiliating Genes
1	Mutant thyroid hormone receptors (TRs) isolated from distinct cancer types display distinct target gene specificities: a unique regu latory repertoire associated with two renal clear cell carcinomas. (21622534)	Rosen M.D.... Privalsky M.L.	2011	THRB, THRA
2	The expression and clinical significance of TGF-beta1 and MMP2 in human renal clear cell carcinoma. (19223381)	Yang S.D.... Zhou Z.Y.	2010	MMP2, TGFB1
3	von Hippel-Lindau-dependent patterns of RNA polymeras e II hydroxylation in human renal clear cell carcinomas. (20978146)	Yi Y.... Czyzyk-Krzeska M.F.	2010	VHL, POLR2A, EGLN1
4	A novel resveratrol analogue HS-1793 treatment overco mes the resistance conferred by Bcl-2 and is associated with the formation of m ature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells. (19885558)	Jeong S.H.... Yoo Y.H.	2009	BCL2
5	P-glycoprotein activity in renal clear cell carcinoma . (18440836)	Soto-Vega E.... Llorente L.	2009	ABCB1
6	siRNA targeting survivin inhibits growth and induces apoptosis in human renal clear cell carcinoma 786-O cells. (19628339)	Zhang Y.... Luo W.	2009	BIRC5
7	Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. (18359287)	Ivanov S.V.... Lerman M.I.	2008	VHL, TGFBI, KLF10
8	Loss of PL6 protein expression in renal clear cell carcinomas and other VHL-deficient tumours. (17973242)	Ivanova A.V.... Lerman M.I.	2008	VHL, TMEM115
9	BMI-1 expression is inversely correlated with the grading of renal clear cell carcinoma. (18347933)	Kozakowski N.... Pammer J.	2008	BMI1
10	Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma. (18351578)	Landriscina M.... Ranieri E.	2008	VDR, CYP24A1
11	Metastatic renal clear cell carcinoma in the parotid gland: a study of immunohistochemical profile and cell adhesion molecules (CAMs) expression in two cases. (17607380)	Andreadis D.... Barbatis C.	2007	DSG2
12	Activation of the mTOR signaling pathway in renal clear cell carcinoma. (17162089)	Robb V.A.... Henske E.P.	2007	PSMC4, MTOR, RHEBL1
13	Diagnostic value of cytokeratin 7, CD10 and mesothelin in distinguishing ovarian clear cell carcinoma from metastasis of renal clear cell carcinoma. (18042078)	Leroy X.... Copin M.C.	2007	MME, KRT7, MSLN
14	Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix. (16740772)	Inamoto T.... Morimoto C.	2006	CDK2, CDKN1B
15	Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. (17177989)	Mignogna C.... Bufo P.	2006	ABCC1, ABCB1
16	Identification of nicotinamide N-methyltransferase as a novel tumor marker for renal clear cell carcinoma. (17070307)	Sartini D.... Emanuelli M.	2006	NNMT
17	Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma. (16152585)	Yamada D.... Murakami Y.	2006	EPB41L3
18	Solitary metachronous metastasis to the thyroid from renal clear cell carcinoma 19 years after nephrectomy: report of a case. (15912297)	Wada N.... Takanashi Y.	2005	TG, NKX2-1
19	Antisense oligonucleotide targeting survivin induces apoptosis of renal clear-cell carcinoma cells and enhances their sensitivity t o epirubicin in vitro (16188142)	Gao X.K.... Kang F.X.	2005	BIRC5
20	Decreased expression of REIC/Dkk-3 in human renal clear cell carcinoma. (14767340)	Kurose K.... Huh N.H.	2004	DKK3
21	Somatic mutations of VHL gene and HIF-1alpha expression in primary renal clear cell carcinomas (15062033)	Guo H.F.... Na Y.Q.	2004	HIF1A, VHL
22	The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. (15180922)	Sufan R.I.... Ohh M.	2004	VHL, RBX1, CUL2
23	Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. (15126876)	Bui M.H.... Belldegrun A.S.	2004	CA9
24	Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. (15145526)	Zimmermann U.... Walther R.	2004	ANXA4
25	Frequent somatic mutations of the von Hippel-Lindau (VHL) tumor suppressor gene and its meaning in sporadic human renal clear cell carcinoma (15100736)	Gong K.... Na Y.Q.	2004	VHL
26	Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. (12576453)	Bui M.H.... Belldegrun A.S.	2003	CA9
27	Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. (12670587)	VisapAoAo H.... Palotie A.	2003	GSN
28	A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. (12819395)	Cameron R.I.... McCluggage W.G.	2003	VIM, KRT7
29	Quantitative RT-PCR assay for MUC3 and VEGF mRNA in renal clear cell carcinoma: relationship with nuclear grade and prognosis. (14550470)	Leroy X.... Porchet N.	2003	VEGFA, MUC3A
30	Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. (12434420)	Currie M.J.... Fox S.B.	2002	TEK, ANGPT1, ANGPT2
31	Expression of mutant thyroid hormone nuclear receptors is associated with human renal clear cell carcinoma. (11756220)	Kamiya Y.... Nauman A.	2002	THRA
32	Type I 5'-iodothyronine deiodinase activity and mRNA are remarkably reduced in renal clear cell carcinoma. (11383912)	Pachucki J.... Nauman A.	2001	DIO1
33	Frequent somatic mutations of the von Hippel-Lindau tumor suppressor gene in primary sporadic human renal clear cell carcinomas (11798864)	Gong K.... Xin D.	2001	VHL
34	Expression of thyroid hormone receptors is disturbed in human renal clear cell carcinoma. (10822129)	Puzianowska-Kuznicka M.... Nauman J.	2000	THRB, THRA
35	Clear cell carcinoma of the liver: a comparative immu nohistochemical study with renal clear cell carcinoma. (10955454)	Murakata L.A.... Nzeako U.C.	2000	RPS27A
36	Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. (10590373)	Gilcrease M.Z.... Albores-Saavedra J.	1999	CD44
37	Carbohydrate metabolism in human renal clear cell carcinomas. (1434530)	Steinberg P.... Thoenes W.	1992	GCK, G6PC, G6PD

Genes related to renal clear cell carcinoma according to GeneCards:

(show top 50)    (show all 87)

id	Symbol	Description	Score	GeneCards Section Context
1	CDH16	cadherin 16, KSP-cadherin	11.0
2	CLDN7	claudin 7	11.0
3	TCEB2	transcription elongation factor B (SIII), polypeptide 2 (18kDa, elongin B)	11.0	Publications
4	AMACR	alpha-methylacyl-CoA racemase	11.0
5	DEFB1	defensin, beta 1	11.0
6	MUC3A	mucin 3A, cell surface associated	11.0	Publications
7	CA9	carbonic anhydrase IX	11.0	Publications
8	FH	fumarate hydratase	11.0
9	VHL	von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase	11.0	Publications
10	KRT7	keratin 7	11.0	Publications
11	INHA	inhibin, alpha	11.0
12	PVALB	parvalbumin	11.0
13	EPOR	erythropoietin receptor	11.0
14	GSN	gelsolin	11.0	Publications
15	S100A1	S100 calcium binding protein A1	11.0
16	AQP2	aquaporin 2 (collecting duct)	11.0
17	CXCR3	chemokine (C-X-C motif) receptor 3	11.0
18	FOLH1	folate hydrolase (prostate-specific membrane antigen) 1	11.0
19	MME	membrane metallo-endopeptidase	11.0	Publications
20	POLR2L	polymerase (RNA) II (DNA directed) polypeptide L, 7.6kDa	11.0
21	RASSF1	Ras association (RalGDS/AF-6) domain family member 1	11.0
22	CALB2	calbindin 2	11.0
23	HIF1A	hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	11.0	Publications
24	TGFBR2	transforming growth factor, beta receptor II (70/80kDa)	11.0
25	SETD2	SET domain containing 2	11.0
26	MTOR	mechanistic target of rapamycin (serine/threonine kinase)	11.0	Publications
27	SLC2A1	solute carrier family 2 (facilitated glucose transporter), member 1	11.0
28	TGFA	transforming growth factor, alpha	11.0
29	VIM	vimentin	11.0	Publications
30	IGF1R	insulin-like growth factor 1 receptor	11.0
31	PTEN	phosphatase and tensin homolog	11.0
32	KDR	kinase insert domain receptor (a type III receptor tyrosine kinase)	11.0
33	BIRC5	baculoviral IAP repeat containing 5	11.0	Publications
34	MUC1	mucin 1, cell surface associated	11.0
35	MET	met proto-oncogene (hepatocyte growth factor receptor)	11.0
36	IGFBP3	insulin-like growth factor binding protein 3	11.0
37	CASP8	caspase 8, apoptosis-related cysteine peptidase	11.0
38	CDH1	cadherin 1, type 1, E-cadherin (epithelial)	11.0
39	CAV1	caveolin 1, caveolae protein, 22kDa	11.0
40	VEGFA	vascular endothelial growth factor A	11.0	Publications
41	FHIT	fragile histidine triad	11.0
42	TMEM115	transmembrane protein 115	11.0	Publications
43	RHEBL1	Ras homolog enriched in brain like 1	11.0	Publications
44	EGLN2	egl nine homolog 2 (C. elegans)	11.0	Publications
45	MAP1LC3C	microtubule-associated protein 1 light chain 3 gamma	11.0	Disorders
46	KLF10	Kruppel-like factor 10	11.0	Publications
47	NNMT	nicotinamide N-methyltransferase	11.0	Publications
48	KHK	ketohexokinase (fructokinase)	11.0
49	CADM4	cell adhesion molecule 4	11.0
50	NEDD8	neural precursor cell expressed, developmentally down-regulated 8	11.0	Publications

Pathways related to renal clear cell carcinoma according to GeneDecks:

(show top 50)    (show all 55)

id	Pathway	Score	Top Affiliating Genes
1	Transcription Receptor-mediated HIF regulation10	10.7	HIF1A, IGFBP3, IGF1R
2	Transcription_Receptor-mediated HIF regulation41	10.6	HIF1A, PTEN, IGFBP3, IGF1R, MTOR, VEGFA
3	Cellular responses to stress38	10.4	EGLN2, EGLN1, CUL2, CA9, VHL
4	Glucose / Energy Metabolism3	10.4	G6PD, PTEN, CA9, AMACR, IGF1R, AQP2
5	Transcription P53 signaling pathway10	10.4	VEGFA, CDK2
6	Breast Cancer Regulation by Stathmin136	10.3	TGFA, TEK, IGF1R
7	ILK Signaling36	10.3	EPOR, TGFA, HIF1A, TEK, IGF1R, MET
8	Signal transduction_AKT signaling41	10.2	MTOR, CDKN1B, MET, IGF1R, PTEN
9	Endothelin-1 Signaling Pathway36	10.2	EPOR, TEK, IGF1R, ANGPT4, ANGPT1
10	Tyrosine Kinases / Adaptors3	10.2	TGFA, TEK, IGF1R, ANGPT2, MET, KDR
11	Adhesion3	10.1	CD44, TGFBI
12	Akt Signaling36	10.1	EPOR, CXCR3, TEK, IGF1R, ANGPT4, ANGPT1
13	Development_Angiopoietin - Tie2 signaling41	10.1	TEK, ANGPT4, ANGPT1, ANGPT2
14	HIF1Alpha Pathway36	10.1	SLC2A1, TCEB2, TCEB1, HIF1A, EGLN2, EGLN1
15	Angiopoietin-TIE2 Signaling36	10.0	TEK, ANGPT4, ANGPT1, ANGPT2, BIRC5
16	Development Angiopoietin - Tie2 signaling10	10.0	TEK, ANGPT4, ANGPT1, ANGPT2, BIRC5
17	p53 Signaling36	10.0	HIF1A, PTEN, CASP8, BCL2
18	Renal cell carcinoma20	10.0	TCEB2, RBX1, VHL, FH, MET, CUL2
19	14-3-3 Induced Intracellular Signaling36	10.0	EPOR, TGFB1, TEK, IGF1R
20	Cell surface interactions at the vascular wall38	9.9	ANGPT2, ANGPT1, ANGPT4, CAV1
21	eNOS Signaling36	9.7	EPOR, TGFB1, TGFA, TEK, CAV1, CASP8
22	Focal adhesion20	9.7	KDR, BCL2, MET, CAV1, PTEN
23	GSK3 Signaling36	9.6	CDH16, CDH1, MET, IGF1R, TEK, TGFA
24	ERK Signaling36	9.4	EPOR, TGFB1, TGFA, TEK, IGF1R, ANGPT4
25	Nanog in Mammalian ESC Pluripotency36	9.4	EPOR, TGFB1, TGFA, TEK, IGF1R, MET
26	p53 Mediated Apoptosis36	9.4	TGFB1, TGFA, PTEN, CASP8, IGF1R, MET
27	Apoptotic Pathways in Synovial Fibroblasts36	9.4	TGFB1, TGFA, CASP8, IGF1R, MET, KDR
28	Prostate cancer20	9.4	TGFA, PTEN, IGF1R, CDKN1B, CDK2, MTOR
29	Cell cycle Regulation of G1/S transition (part 1)10	9.3	TGFBR2, TGFB1, CDKN1B, CDK2, RBX1
30	Cell cycle_Regulation of G1/S transition (part 1)41	9.3	TGFBR2, TGFB1, CDKN1B, CDK2, RBX1
31	Mitochondrial Apoptosis36	9.3	TGFB1, TGFA, CASP8, IGF1R, MET, BCL2
32	DHA Signaling36	9.3	TGFB1, TGFA, CASP8, IGF1R, MET, BCL2
33	Vinka Alkaloid Pathway, Pharmacokinetics34	9.2	ABCC1, ABCB1, BCL2
34	SOCS Pathway36	9.1	PSMC4, TCEB2, TCEB1, CUL2, ANGPT4, ANGPT1
35	Cellular Apoptosis Pathway36	9.0	TGFB1, TGFA, CASP8, IGF1R, MET, BCL2
36	Estrogen Pathway36	9.0	EPOR, POLR2A, TGFB1, TGFA, TEK, IGF1R
37	TGF-Beta Pathway36	8.9	TGFBR2, TGFB1, TGFA, ANGPT4, ANGPT1, ANGPT2
38	JNK Pathway36	8.9	EPOR, TGFB1, TEK, ANGPT4, ANGPT1, ANGPT2
39	Transcription_P53 signaling pathway41	8.9	MMP2, CDK2, BCL2, KDR, VEGFA
40	PAK Pathway36	8.9	TGFB1, KDR, BCL2, MET, ANGPT2, ANGPT1
41	MAPK Family Pathway36	8.9	TGFBR2, TGFB1, TGFA, ANGPT4, ANGPT1, ANGPT2
42	Angiogenesis3	8.8	TGFB1, TGFA, HIF1A, EGLN1, TEK, CA9
43	Tec Kinases Signaling36	8.7	EPOR, CXCR3, TGFB1, TGFA, TEK, IGF1R
44	p38 Signaling36	8.7	TEK, TGFA, TGFB1, CXCR3, EPOR, IGF1R
45	Antioxidant Action of Vitamin-C36	8.7	SLC2A1, CXCR3, TGFB1, TGFA, TEK, IGF1R
46	Rho Family GTPases36	8.6	EPOR, TGFB1, TGFA, TEK, IGF1R, ANGPT4
47	JAK-STAT Pathway36	8.2	CUL2, TGFA, TGFB1, TCEB1, TCEB2, PSMC4
48	Molecular Mechanisms of Cancer36	7.8	CASP8, TEK, PTEN, HIF1A, TGFA, TGFB1
49	Pancreatic Adenocarcinoma36	7.7	TEK, TGFA, TGFB1, TGFBR2, EPOR, IGF1R
50	Pathways in cancer20	7.0	TGFB1, TGFBR2, TCEB1, TCEB2, SLC2A1, TGFA

Compounds related to renal clear cell carcinoma according to GeneDecks:

(show top 50)    (show all 239)

id	Compound	Score	Top Affiliating Genes
1	glucose32	10.3	SETD2, VHL, MME, FH, GSN, ANGPT2
2	egcg32	10.0	CDK2, IGFBP3, G6PD
3	pge232	9.9	SETD2, CDH1, MME, AQP2, ANGPT2, IGF1R
4	dihydrotestosterone32 9 18 9	12.6	SETD2, VIM, VDR, CDK2, FOLH1, GSN
5	trastuzumab32 34 9 9	12.4	VEGFA, BIRC5, KDR, MUC1, CDK2, CDKN1B
6	rapamycin32 42	10.1	VIM, VHL, VEGFA, KDR, MTOR, CDK2
7	5-aza-2deoxycytidine32	8.9	VIM, VHL, RASSF1, CDH1, FHIT, IGFBP3
8	nitric oxide32 9 18 9	11.7	GCK, VHL, BIRC5, KDR, MUC1, S100A1
9	glycogen32 18	9.7	GCK, SETD2, VIM, VHL, MTOR, S100A1
10	agar32	8.7	VIM, RASSF1, BIRC5, MUC1, CDK2, CDKN1B
11	steroid32	8.3	RBX1, BIRC5, MUC3A, MTOR, CD44, MME
12	gefitinib32 34 9 9	11.2	VIM, VEGFA, BIRC5, KDR, MTOR, CDK2
13	folate32	8.1	VIM, VHL, VDR, RASSF1, KDR, MUC1
14	arginine32	8.0	GCK, VDR, CDK2, CD44, MME, AQP2
15	adriamycin32	8.0	VIM, VDR, BIRC5, BCL2, MUC1, CD44
16	ly29400232	7.9	GCK, VHL, VEGFA, CDKN1B, CD44, CDH1
17	vitamin d32	7.8	VIM, VDR, CDK2, CD44, CDH1, GSN
18	retinoic acid32 42 18	9.8	GCK, SETD2, VDR, RASSF1, BIRC5, KDR
19	oligonucleotide32	7.8	GCK, SETD2, VIM, VHL, RASSF1, BIRC5
20	matrigel32	7.7	VIM, VEGFA, KDR, MUC1, MTOR, CD44
21	wortmannin32 42	8.7	SETD2, VIM, BIRC5, KDR, BCL2, MTOR
22	progesterone32 42 9 18 9	11.7	GCK, SETD2, BIRC5, BCL2, S100A1, CDK2
23	docetaxel32 34 9 9	10.6	SETD2, VEGFA, VDR, BIRC5, KDR, BCL2
24	oxygen32 18	8.6	GCK, SETD2, BIRC5, BCL2, CDK2, CDKN1B
25	celecoxib32 42 34 9 18 9	12.5	VEGFA, BIRC5, KDR, BCL2, CDK2, CDKN1B
26	doxorubicin32 34 9 9	10.4	SETD2, VIM, KDR, MTOR, CDK2, CDKN1B
27	arsenite32 18	8.4	SETD2, VEGFA, VDR, BIRC5, BCL2, MTOR
28	atp32	7.2	GCK, SETD2, BIRC5, KHK, MTOR, CDK2
29	butyrate32	7.1	GCK, SETD2, VIM, VDR, BIRC5, BCL2
30	calcium32 9 18 9	10.1	GCK, VHL, BIRC5, MUC1, MUC3A, S100A1
31	alanine32	7.0	GCK, VDR, RASSF1, BIRC5, CDK2, CDKN1B
32	cysteine32	6.9	GCK, VDR, KDR, MUC1, S100A1, CD44
33	lactate32	6.8	GCK, SETD2, VIM, BIRC5, KDR, CD44
34	thymidine32 18	7.8	VDR, BIRC5, KDR, MUC1, CDK2, CDKN1B
35	5fluorouracil32	6.8	VEGFA, VDR, BIRC5, KDR, BCL2, MUC1
36	phosphatidylinositol32	6.5	SETD2, VHL, BIRC5, KDR, BCL2, MTOR
37	cyclosporin a32 42	7.5	VDR, KDR, MTOR, CDK2, CD44, MME
38	etoposide32 42 9 9	9.4	SETD2, BIRC5, BCL2, CDK2, CDKN1B, CD44
39	tamoxifen32 34 9 9	9.4	VIM, VEGFA, VDR, BIRC5, KDR, BCL2
40	estrogen32	6.2	KLF10, SETD2, VHL, VDR, BMI1, RASSF1
41	genistein32 9 18 9	9.2	SETD2, VIM, VEGFA, VDR, BIRC5, KDR
42	actinomycin d32	6.0	SETD2, VIM, VHL, VEGFA, VDR, BIRC5
43	vegf32	5.9	SETD2, VHL, KDR, BCL2, MUC1, MTOR
44	testosterone32 9 18 9	8.8	SETD2, VIM, VDR, BIRC5, MUC1, MTOR
45	cycloheximide32	5.6	SETD2, VIM, VEGFA, VDR, BIRC5, BCL2
46	cisplatin32 34 9 9	8.5	SETD2, VEGFA, RASSF1, BIRC5, KDR, BCL2
47	paraffin32	5.4	VIM, VEGFA, BIRC5, KDR, BCL2, MUC1
48	dexamethasone32 42 34 9 9	9.4	GCK, VIM, VEGFA, VDR, BIRC5, KDR
49	tyrosine32	4.7	SETD2, VHL, VEGFA, BIRC5, KDR, MUC1
50	serine32	3.8	GCK, SETD2, VIM, VHL, VDR, RASSF1

Cellular components related to renal clear cell carcinoma according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	Cul2-RING ubiquitin ligase complex	GO:031462	10.1	TCEB2, CUL2, RBX1
2	basolateral plasma membrane	GO:016323	9.6	SLC2A1, TGFA, ABCC1, TEK, CAV1, AQP2
3	cell surface	GO:009986	8.6	TGFA, ABCB1, TEK, CAV1, CDH1, CD44
4	nucleoplasm	GO:005654	7.3	GCK, THRB, TCEB1, TCEB2, PSMD6, PSMC4
5	extracellular region	GO:005576	7.2	ANGPT4, IGFBP3, TEK, TG, TGFB1, TGFBI
6	plasma membrane	GO:005886	6.8	PTEN, DIO1, RPS27A, RHEBL1, ABCB1, ABCC1
7	cytosol	GO:005829	6.4	EGLN1, RPS27A, NNMT, CUL2, PTEN, G6PD
8	cytoplasm	GO:005737	6.4	RHEBL1, PTEN, TEK, CASP8, CALB2, AMACR
9	nucleus	GO:005634	4.5	HIF1A, ABCC1, EGLN2, EGLN1, KRT7, PTEN

Biological processes related to renal clear cell carcinoma according to GeneDecks:

(show all 32)

id	Name	GO ID	Score	Top Affiliating Genes
1	cellular component disassembly involved in apoptotic process	GO:006921	10.4	DSG2, CASP8, GSN, CDH1, VIM
2	positive regulation of endothelial cell proliferation	GO:001938	10.3	HIF1A, TEK, MTOR, KDR, VEGFA
3	Tie receptor signaling pathway	GO:048014	10.2	TEK, ANGPT1, ANGPT2
4	positive regulation of angiogenesis	GO:045766	10.2	HIF1A, TEK, ANGPT4, ANGPT2, KDR, VEGFA
5	glomerulus vasculature development	GO:072012	10.1	ANGPT2, ANGPT1, TEK
6	positive regulation of endothelial cell migration	GO:010595	10.1	TEK, ANGPT4, ANGPT1, KDR, VEGFA
7	negative regulation of endothelial cell apoptotic process	GO:2000352	10.0	TEK, ANGPT1, KDR
8	positive regulation of focal adhesion assembly	GO:051894	10.0	VEGFA, KDR, TEK
9	phosphatidylinositol-mediated signaling	GO:048015	10.0	PTEN, IGF1R, GSN, CDKN1B, MTOR
10	positive regulation of peptidyl-tyrosine phosphorylation	GO:050731	9.8	ANGPT4, ANGPT1, CD44, MTOR, VEGFA
11	positive regulation of blood vessel endothelial cell migration	GO:043536	9.8	VEGFA, ANGPT1, ANGPT4, TGFB1
12	lactation	GO:007595	9.7	HIF1A, CAV1, MET, VDR
13	regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:061418	9.6	TCEB2, RBX1, VHL, VEGFA, CA9, CUL2
14	cellular response to stress	GO:033554	9.6	EGLN1, EGLN2, HIF1A, TCEB1, TCEB2, RPS27A
15	ovarian follicle development	GO:001541	9.5	KDR, BCL2, INHA, ANGPT1
16	virus-host interaction	GO:019048	9.5	TCEB1, TGFB1, KRT7, CUL2, CAV1, CASP8
17	cellular response to hypoxia	GO:071456	9.4	RBX1, VHL, VEGFA, MTOR, ANGPT4, CA9
18	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	GO:006977	9.4	PSMC4, PSMD6, RPS27A, CDKN1B, CDK2, MUC1
19	positive regulation of gene expression	GO:010628	9.2	NKX2-1, TGFB1, MET, CD44, VDR, VEGFA
20	positive regulation of cell proliferation	GO:008284	9.1	TGFBR2, TGFB1, PTEN, IGF1R, CDKN1B, CDK2
21	negative regulation of cell proliferation	GO:008285	9.1	TGFB1, CUL2, PTEN, TMEM115, IGFBP3, CDKN1B
22	epidermal growth factor receptor signaling pathway	GO:007173	9.1	TGFB1, TGFA, RPS27A, PTEN, CDKN1B, MTOR
23	angiogenesis	GO:001525	9.0	CXCR3, TGFBI, TGFA, HIF1A, PTEN, TEK
24	apoptotic process	GO:006915	9.0	CXCR3, PSMC4, PSMD6, TGFBR2, DSG2, RPS27A
25	anti-apoptosis	GO:006916	8.8	TGFA, RPS27A, TEK, IGF1R, ANGPT4, ANGPT1
26	response to hypoxia	GO:001666	8.8	TGFB1, HIF1A, EGLN2, EGLN1, CAV1, ANGPT1
27	negative regulation of apoptotic process	GO:043066	8.7	PTEN, TEK, IGF1R, ANGPT4, ANGPT1, CD44
28	positive regulation of peptidyl-serine phosphorylation	GO:033138	8.7	TGFB1, TEK, CAV1, ANGPT1, MET, CD44
29	G1/S transition of mitotic cell cycle	GO:000082	8.6	PSMC4, PSMD6, RPS27A, CUL2, CDKN1B, CDK2
30	negative regulation of transcription from RNA polymerase II promoter	GO:000122	8.6	NKX2-1, TGFB1, THRB, RPS27A, CAV1, S100A1
31	response to drug	GO:042493	8.5	ABCC1, TGFA, TGFB1, TGFBR2, ABCB1, NNMT
32	small molecule metabolic process	GO:044281	8.3	NNMT, ABCB1, G6PC, G6PD, PSMD6, PSMC4

Molecular functions related to renal clear cell carcinoma according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	enzyme binding	GO:019899	9.4	THRB, HIF1A, PTEN, CAV1, BIRC5, VHL
2	identical protein binding	GO:042802	9.4	EPOR, SLC2A1, CASP8, IGF1R, S100A1, BCL2
3	ubiquitin protein ligase binding	GO:031625	8.9	NEDD8, POLR2A, TCEB2, HIF1A, CUL2, BCL2
4	protein binding	GO:005515	2.4	EPOR, EGLN1, KRT7, CUL2, PTEN, TEK